We use cookies to enhance your experience. By continuing to browse this site you agree to our use of cookies. More info.
Lawmakers across the United States continue to debate the safety of kratom, an opioid-containing plant that has been listed as a "drug of concern" by the U.S. Food and Drug Administration. Kratom is sold over the counter in specialty stores and online.
Substance use disorders are a major health concern in the U.S. and a growing number of people suffering from these diseases are self-medicating with kratom to help break a cycle of dependence. After tobacco, the most commonly abused substance in the U.S. is alcohol with nearly 15 million people diagnosed with an alcohol use disorder.
A Purdue University team published a paper in the Nov. 8 edition of the British Journal of Pharmacology examining the effects of kratom and the potential impacts on people with alcohol use disorder. The cost to individuals and society from alcohol use is estimated at more than $250 billion each year.
One big challenge is that alcohol use disorder is not adequately treated with currently available medications; in fact less than 10% of patients receive treatment. Few broadly effective drug therapies exist to treat alcohol use disorder, so finding new and better treatments is of critical importance to help people manage their disease."
Richard van Rijn, associate professor in Purdue's College of Pharmacy, who led the research team
The Purdue scientists, in collaboration with researchers at Memorial Sloan-Kettering and Washington University, studied the potential effects of kratom and its components on the body and in the ability to reduce alcohol consumption.
"Our work shows that kratom may be effective to self-medicate alcohol use disorder but is not entirely safe," van Rijn said. "Instead, our research provides additional support for other therapies that would not produce the obvious side effects of using kratom, which may be addictive."
The Purdue team previously focused on a G protein-coupled receptor, called the delta opioid receptor, which is a novel drug target that is different from the receptor in the body that binds prescription opioids. They developed drugs that bind to this new target and selectively activate a particular protein signaling cascade of this receptor.
Gutridge, A.M., et al. (2019) G protein‐biased kratom‐alkaloids and synthetic carfentanil‐amide opioids as potential treatments for alcohol use disorder. British Journal of Pharmacology. doi.org/10.1111/bph.14913.
Posted in: Medical Science News | Medical Research News | Medical Condition News
Tags: Alcohol, Alcohol-Use Disorder, Drugs, Food, Opioids, Pharmacology, Pharmacy, Protein, Receptor, Research, Tobacco
In this interview, we speak to Charles Wells from Gates MRI about their current research into tuberculosis (TB) as well as the recent updated guidelines for TB care.
In this interview, we speak to Dr. Jordan Green about his latest research partnership with Modality.AI that investigated whether an app could be used to effectively diagnose speech decline due to ALS.
In this interview, we speak to Tom Kostrzewski, VP of Science and Technology at CN Bio, about their organ-on-a-chip product and the future of drug discovery.
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.
This site complies with the HONcode standard for trustworthy health information: verify here.
News-Medical.net - An AZoNetwork Site
Owned and operated by AZoNetwork, © 2000-2022